Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. EASL. Recommendations on Treatment of Hepatitis C 2016, update of September 2016,
http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf
(September 2016).
2. Terrault, N. A. et al. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology 151, 1131–1140 e1135,
https://doi.org/10.1053/j.gastro.2016.08.004
(2016).
3. Wyles, D. L. & Luetkemeyer, A. F. Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. Topics in antiviral medicine 25, 103–109 (2017).
4. Pawlotsky, J. M. & Hepatitis, C. Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 151, 70–86,
https://doi.org/10.1053/j.gastro.2016.04.003
(2016).
5. Sarrazin, C. et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology 151, 501–512 e501,
https://doi.org/10.1053/j.gastro.2016.06.002
(2016).